S&P 500 Consumer Staples Sector SEC Filings — May 20, 2026

20-05-2026

Morgan Stanley Solana Trust, a Delaware-based grantor trust, filed Amendment No. 1 to Form S-1 on May 20, 2026, to register common shares of beneficial interest (Shares) for an exchange-traded fund listed on NYSE Arca. The trust seeks to passively track the performance of SOL (the native token of Solana) using the CoinDesk Solana Benchmark 4PM NY Settlement Rate, and will also engage in staking a portion of its SOL to generate rewards, distributing them monthly. The filing details the roles of Morgan Stanley Investment Management Inc. as Delegated Sponsor, CSC Delaware Trust Company and AGS Trustees as trustees, and BNY Mellon and Coinbase Custody Trust Company as SOL custodians, with cash creations and redemptions facilitated through Authorized Participants and SOL Counterparties.

• · The trust intends to make monthly (at least quarterly) distributions of staking rewards.
• · Morgan Stanley Investment Management Inc. (Delegated Sponsor) has discretion to determine whether staking creates undue legal or regulatory risk, including tax qualification risk.
• · Shares are expected to be listed on NYSE Arca; the trust is a grantor trust for U.S. federal income tax purposes.
• · Trust will not use leverage, derivatives, or similar instruments.
• · Authorized Participants can purchase shares with cash (via a SOL Counterparty) or in-kind with SOL; redemptions similarly may be cash or in-kind.
• · Baskets are 10,000 Shares each; Shares are not redeemable outside Basket aggregations except in liquidation.
• · The Cayman Trustee is a wholly owned subsidiary of Appleby Global Services (Cayman) Limited, a regulated entity under the Cayman Islands Monetary Authority.

20-05-2026

Haemonetics Corp reported a 2.0% decline in net revenues to $1,334,027K for fiscal year 2026, with a significant 42.0% drop in net income to $97,308K compared to $167,679K in FY2025. While gross profit improved 5.2% to $787,586K and gross margin expanded to 59.0% from 55.0%, operating income fell 29.3% to $156,734K due to a 19.7% increase in operating expenses, driven by a $86,546K impairment of intangible assets. Segment performance was mixed: Hospital net revenues grew 4.3% (led by Blood Management Technologies +14.6%), but Plasma revenues declined 2.0% and Blood Center revenues fell 15.3% (Whole Blood -99.2%).

• · Net debt position worsened to $979,140K from $918,025K in FY2025.
• · Working capital improved to $552,280K from $356,862K, and current ratio increased to 3.0 from 1.6.
• · Days sales outstanding remained stable at 56 days vs 55 days.
• · Inventory turnover improved slightly to 1.5 from 1.4.
• · Net cash used in investing activities increased to $179,547K from $161,895K.
• · Financing activities swung to a net use of $178,460K from a net source of $108,818K.
• · US revenue declined 2.8% (reported) while International revenue grew 0.6% (reported), but constant currency growth was negative for both (US -2.8%, International -2.6%).
• · Revenue mix shifted: US share decreased to 73.6% from 74.3%, Europe increased to 13.9% from 12.9%, Japan increased to 5.1% from 4.6%.
• · SG&A expense as a percentage of net revenues increased to 33.2% from 32.1%.
• · R&D expense as a percentage of net revenues decreased slightly to 4.5% from 4.6%.

20-05-2026

Philip Morris International announced the appointment of Massimo Andolina as Group CFO, effective August 1, 2026, succeeding Emmanuel Babeau, who will remain as Strategic Advisor until March 31, 2027. Andolina, previously President of the Europe Region, led robust top- and bottom-line growth in the region, while Babeau oversaw strong financial performance and the acquisition of Swedish Match during his tenure. The smoke-free business accounted for 43% of Q1 2026 net revenues, but the company faces ongoing risks including regulatory restrictions, excise tax increases, and geopolitical instability.

• · Andolina joined PMI in 2008 and served as SVP Global Operations from 2018 to 2023, leading a team of over 30,000 people.
• · Babeau was appointed CFO in May 2020 and led the acquisition of Swedish Match in 2022.
• · Smoke-free products are available in over 105 markets and used by over 43 million legal-age consumers as of December 31, 2025.
• · The U.S. FDA has authorized marketing of Swedish Match's General snus and ZYN nicotine pouches, as well as versions of IQOS devices and consumables.
• · Andolina holds a Master of Science in Mechanical and Industrial Engineering from the University of Palermo and an MBA from IMD in Lausanne.

20-05-2026

Castellum, Inc. held its 2026 Annual Meeting on May 19, 2026, where all five director nominees were elected and both proposals (ratification of RSM US LLP as auditor and amendment to the Stock Incentive Plan) were approved. While the auditor ratification and director elections passed overwhelmingly, the stock incentive plan amendment faced notable shareholder opposition with approximately 40% of votes cast against it.

• · The stock incentive plan amendment to increase aggregate shares reserved to 13,000,000 passed with 19,780,876 For, 13,632,126 Against, and 303,514 Abstentions, excluding 22,789,172 broker non-votes.
• · A quorum was present for the meeting and total shares outstanding eligible to vote were not disclosed, but broker non-votes were 22,789,172 on director elections and the incentive plan.
• · All five incumbent director nominees were re-elected, but four of five received over 20% withhold votes (Alarie 20.6%, Campbell 22.7%, Champoux 20.0%, McMillen 22.0%); only Glen R. Ives received notably lower withhold votes at 13.7%.
• · Auditor ratification proposal did not have broker non-votes, suggesting it was considered a routine matter under NYSE rules.

20-05-2026

Clean Harbors announced the retirement of founder and Executive Chairman Alan S. McKim, who will step down from the Board and his role as Chief Technology Officer once a new independent Chair is appointed later this summer. The company highlighted McKim's 46-year tenure, during which it grew from a single truck to a $6B+ revenue, 25,000-employee firm. The leadership transition is planned and orderly, with co-CEOs Eric Gerstenberg and Mike Battles continuing to lead the company.

• · McKim founded Clean Harbors in 1980 and served as Chairman and CEO until 2023, when he transitioned to Executive Chairman and CTO.
• · The Board expects to appoint an independent Chair later this summer.
• · McKim holds an MBA from Northeastern University's D'Amore-McKim School of Business and honorary doctorates from Northeastern and Massachusetts Maritime Academy.
• · McKim is the author of 'Doing the Doing', chronicling Clean Harbors' growth.
• · The company serves a majority of Fortune 500 companies and operates in the U.S., Canada, Mexico, Puerto Rico, and India.

20-05-2026

Northwest Pipeline LLC, along with The Williams Companies, Inc. and Transcontinental Gas Pipe Line Company, LLC, entered into a $3,750,000,000 Senior Unsecured Revolving Credit Facility dated May 19, 2026, with Wells Fargo Bank as Administrative Agent and a syndicate of major banks. The agreement amends and restates a prior credit facility. The applicable interest rate spreads and commitment fees are determined based on the Index Debt ratings of The Williams Companies, Inc., ranging from 0.875% (Term SOFR) for A/A2 rated debt to 1.500% for BBB-/Baa3 rated debt, with no negative financial covenant limits or declines reported.

• · The borrowers are The Williams Companies, Inc., Northwest Pipeline LLC, and Transcontinental Gas Pipe Line Company, LLC.
• · Wells Fargo Bank, National Association serves as Administrative Agent, with Wells Fargo Securities, LLC and Citibank, N.A. as Joint Lead Arrangers and Joint Bookrunners.
• · The facility matures on a date to be determined per extension options (Section 2.04), with no specific maturity date disclosed in the filing excerpt.
• · The Alternate Base Rate is defined as the greatest of Prime Rate, Federal Funds Effective Rate plus 0.5%, and Term SOFR for one-month plus 1%, subject to a 1% floor.
• · The facility is used for general corporate purposes, as indicated in Section 5.08, and is unsecured.

20-05-2026

Eli Lilly completed an $8.94 billion net proceeds debt offering across 8 tranches: $750M Floating Rate Notes due 2028, $500M Floating Rate Notes due 2029, and $6.25B in Fixed Rate Notes due 2029-2066. Proceeds will partially fund the pending Centessa Acquisition, with $5.25B aggregate principal of the notes subject to special mandatory redemption at 101% if the acquisition is not closed by March 31, 2027 or abandoned. The offering was underwritten by Morgan Stanley, Citigroup, Deutsche Bank, and Goldman Sachs.

• · Fixed Rate Notes due 2056 and 2066 are the longest-dated tranches at 30 and 40 years respectively.
• · The Indenture dates from February 1, 1991 and is with Deutsche Bank Trust Company Americas as trustee.
• · Underwriting agreement dated May 6, 2026; offering completed on May 20, 2026.
• · The 2028 Floating Rate Notes, 2056 Notes, and 2066 Notes are not subject to Centessa Special Mandatory Redemption, even if the acquisition fails.
• · Registration statement on Form S-3 (File No. 333-285052) was used for the offering.
• · Floating rate notes accrue interest quarterly; fixed rate notes pay semi-annually.

20-05-2026

KonaTel, Inc. reported a net loss of $282,590 for Q1 2026, a significant improvement from the $917,528 net loss in Q1 2025. Revenue declined 12.2% to $1,905,062 from $2,168,714 in the prior year period, but gross profit improved 23.6% to $805,604 due to a sharp reduction in cost of revenue. The company's cash position decreased to $665,068 from $704,867 at year-end 2025, and total stockholders' equity fell to $196,220 from $384,205.

• · Operating loss improved to $281,215 from $929,645 in Q1 2025, a 69.7% improvement.
• · Cost of Revenue decreased 27.5% to $1,099,458 from $1,516,821, driving the gross profit improvement despite lower revenue.
• · Payroll and Related Expenses decreased 30.9% to $601,643 from $871,362.
• · Stock Option Expense decreased 60.5% to $94,605 from $239,337.
• · Professional and Other Expenses decreased 46.7% to $83,942 from $157,431.
• · Cash used in operating activities was $39,650 in Q1 2026, compared to cash provided by operations of $269,037 in Q1 2025.
• · Accounts Receivable decreased 49.7% to $142,884 from $284,167, providing $121,781 in operating cash flow.
• · Total liabilities increased slightly to $2,090,251 from $2,080,074.
• · The company's accumulated deficit grew to $10,366,733 from $10,084,143.
• · No income tax expense was recorded for either period.

20-05-2026

Renewal Fuels, Inc. (RNWF) reported a net loss of $669,750 for Q1 2026, a significant increase from the $100,000 loss in Q1 2025, driven by a surge in operating expenses to $632,583 from $100,000. Cash and cash equivalents rose sharply to $99,594 from $2,525 at year-end 2025, primarily due to $513,000 in proceeds from prepaid warrants. However, the company remains deeply insolvent with a stockholders' deficit of $1,110,070 and total liabilities of $1,209,664 exceeding total assets of $99,594.

• · Operating expenses surged to $632,583 in Q1 2026 from $100,000 in Q1 2025, driven by $390,104 in professional fees and $190,932 in advertisement and marketing expenses.
• · Cash provided by financing activities was $513,000 from prepaid warrants, while cash used in operating activities was $415,931.
• · Notes payable to related parties increased to $491,186 from $473,523, with the largest being the CMB Communications June 2023 Note at $157,026.
• · Litigation liability rose slightly to $682,381 from $671,377.
• · The company has a net operating loss carryforward of $20,825,433, fully offset by a valuation allowance, resulting in no deferred tax asset.
• · Common stock issuable of $240,000 was recorded at March 31, 2026, compared to $0 at December 31, 2025.
• · Additional paid-in capital decreased sharply to $5,284,199 from $16,216,112, reflecting stock-based compensation and warrant issuances.

20-05-2026

Morgan Stanley Ethereum Trust filed Amendment No.1 to its S-1 registration statement on May 20, 2026, for an IPO of shares to be listed on NYSE Arca. The trust aims to track ether's price and staking rewards, with staking activities commencing at offering. The filing includes details on custodians (BNY and Coinbase Custody), staking services providers, and creation/redemption mechanisms. No financial figures are provided in this preliminary prospectus.

• · The trust is structured as a grantor trust for U.S. federal income tax purposes.
• · Staking rewards will be distributed monthly (at least quarterly) to shareholders.
• · Authorized Participants can create/redeem shares in cash or in-kind.
• · The trust will not use leverage, derivatives, or similar arrangements.
• · The Delegated Sponsor may allocate ether between custodians (BNY and Coinbase Custody) at its discretion.

20-05-2026

AITX announced that its subsidiary RAD has signed an agreement with a global healthcare organization. The filing is a Form 8-K furnished under Item 8.01, with the press release attached as Exhibit 99.1. No financial terms or specific performance metrics were disclosed, and the filing is not deemed filed for Exchange Act purposes.

• · The agreement is with a global healthcare organization (name not disclosed).
• · The press release was issued on May 20, 2026.
• · The filing is furnished under Item 8.01 and is not deemed filed under Section 18 of the Exchange Act.

20-05-2026

CorVel Corp reported fiscal year 2026 revenue of $959M (+7% YoY) and EPS of $2.14 (+17% YoY). Q4 revenue was $249M (+7% YoY) with EPS of $0.61 (+20% YoY). The company ended the quarter with $233M cash and no debt, while repurchasing $20.1M of stock. However, gross margin remained flat at 25% and general and administrative expenses decreased slightly.

• · Cash increased from $170.6M to $233.1M YoY.
• · No borrowings outstanding.
• · Stock repurchases of $20.1M during Q4.
• · General and administrative expenses decreased from $24.6M to $23.3M in Q4.
• · Income from operations increased to $39.7M from $33.3M in Q4.
• · Customer deposits increased to $115.7M from $101.5M.
• · Accounts receivable decreased to $101.3M from $104.1M.
• · Property, net increased to $117.9M from $92.1M.
• · Goodwill and other assets decreased to $41.6M from $46.4M.
• · Retained earnings grew to $1,013.4M from $903.1M.

20-05-2026

Krystal Biotech held its 2026 Annual Meeting on May 15, 2026, where stockholders re-elected Class III directors Krish S. Krishnan and Christopher Mason, ratified KPMG LLP as independent auditor for FY2026, and approved, on an advisory basis, executive compensation and the Non-Employee Director Compensation Policy. All proposals passed with strong shareholder support, though Proposal Four (director compensation) had a significant number of abstentions (3.2M) and was subject to a special voting exclusion due to ongoing litigation.

• · Krish S. Krishnan received 23,802,920 votes for and 3,079,194 withheld; Christopher Mason received 22,581,854 votes for and 4,300,260 withheld.
• · Proposal Two (ratification of KPMG) passed with 28,443,155 votes for, 15,434 against, and 4,998 abstentions.
• · Proposal Three (advisory vote on executive compensation) passed with 25,679,318 votes for, 1,195,788 against, 7,008 abstentions, and 1,581,473 broker non-votes.
• · Proposal Four (Non-Employee Director Compensation Policy) passed with 21,374,021 votes for, 2,349,550 against, 3,158,543 abstentions, and 1,581,473 broker non-votes; the policy was approved by unaffiliated stockholders, excluding board members and defendants in the litigation Corbin v. Janney, et al., C.A. No. 2025-1051-KSJM (Del. Ch.).

20-05-2026

Select Medical Holdings Corp. received a non-binding proposal from Executive Chairman Ortenzio, CEO Chernow, and Jackson to acquire all outstanding shares for $16.00-$16.20 per share in cash, representing a 15% premium. A Special Committee of independent directors was formed to evaluate the proposal. The merger is expected to close in mid-2026, subject to regulatory approvals and stockholder vote.

• · The HSR Act waiting period expired on April 27, 2026.
• · Appraisal rights are available under DGCL for dissenting stockholders.
• · The Special Committee was formed on November 24, 2025.
• · The November Proposal was publicly disclosed via Schedule 13D on November 24, 2025.
• · The Buyer Consortium includes Ortenzio, Jackson, and Welsh Carson funds.
• · The merger is taxable for U.S. federal income tax purposes.

20-05-2026

Dorian LPG reported strong Q4 FY2026 results with revenues of $153.3M (up 102% YoY) and net income of $81.0M ($1.90 EPS), compared to $8.1M ($0.19 EPS) in Q4 FY2025. For the full fiscal year, revenues were $481.5M (up 36.3% YoY) and net income was $193.7M ($4.54 EPS), versus $90.2M ($2.14 EPS) in FY2025. The company declared an irregular cash dividend of $1.00 per share ($42.8M) and completed the sale of the VLGC Cobra for $81.9M. However, general and administrative expenses increased significantly by 60.9% in Q4 and 24.4% for the full year, and interest income declined.

• · The Baltic LPG Index averaged $90.453 in Q4 FY2026 vs $51.715 in Q4 FY2025, a 75% increase.
• · Available days for the fleet increased from 8,776 in FY2025 to 9,113 in FY2026.
• · Chartered-in fleet expanded from four to six vessels, increasing chartered-in days from 1,460 to 1,923 in FY2026.
• · Unrealized gain on derivatives was $0.6M in Q4 FY2026 vs a loss of $2.6M in Q4 FY2025.
• · Realized gain on derivatives decreased to $0.3M in Q4 FY2026 from $1.1M in Q4 FY2025.
• · Average SOFR rate on the 2023 A&R Debt Facility was lower in Q4 FY2026 compared to Q4 FY2025.
• · The company prepaid $16.5M of the 2023 A&R Debt Facility related to the sold VLGC Cobra.

20-05-2026

Celcuity Inc. appointed Charles (Chip) R. Romp as an independent director on February 11, 2026, increasing the board size from seven to eight members. He was subsequently appointed to the Compensation Committee and the Nominating and Corporate Governance Committee on May 14, 2026. Mr. Romp will receive standard non-employee director compensation, including a $70,000 annual cash retainer and a $135,000 annual equity award, and was granted 215 shares of restricted stock that vested on April 30, 2026.

• · Mr. Romp was appointed to the Compensation Committee and the Nominating and Corporate Governance Committee on May 14, 2026.
• · The restricted stock grant of 215 shares vested in full on April 30, 2026.
• · No arrangements or understandings exist between Mr. Romp and any other persons regarding his selection as director.
• · No reportable relationships or related transactions under Item 404(a) of Regulation S-K.

20-05-2026

XWELL, Inc. reported a net loss of $11.2M for Q1 2026, more than doubling from a $4.7M loss in Q1 2025, driven by a $5.6M non-cash charge from the change in fair value of derivative liabilities and a 5.5% decline in total revenue to $6.6M. However, gross profit improved sharply to $2.4M from $1.3M, and the company strengthened its balance sheet by raising $28.3M in a Series H preferred stock private placement, extinguishing $9.0M of preferred stock and convertible notes, and boosting cash to $16.8M from $2.6M at year-end 2025.

• · Services revenue declined 5.5% YoY to $6.1M from $6.4M; product revenue fell 4.8% to $574K from $603K.
• · Cost of sales decreased 24.9% YoY to $4.3M, driven by a 25.0% drop in labor costs ($3.0M vs $4.0M) and a 32.9% drop in occupancy costs ($761K vs $1.1M).
• · General and administrative expenses surged 76.2% to $7.6M from $4.3M, largely due to stock-based compensation of $886K (vs $83K) and other non-cash charges.
• · The company recorded a $5.6M non-cash charge for the change in fair value of derivative liabilities, compared to a $142K charge in Q1 2025.
• · A $9.0M cash payment was made to repurchase preferred stock, convertible notes and warrants, funded by the $28.3M private placement.
• · Total equity swung from a deficit of $12.8M at year-end 2025 to positive equity of $10.1M at March 31, 2026.
• · Basic and diluted loss per share widened to $1.51 from $1.00, reflecting a higher net loss and increased share count.
• · Accumulated deficit grew to $500.9M from $489.7M at year-end 2025.

20-05-2026

Wheeler Real Estate Investment Trust, Inc. announced that interest on its 7.00% Subordinated Convertible Notes due 2031 payable on June 30, 2026 to holders of record as of June 1, 2026 will be paid in the form of Series D Cumulative Convertible Preferred Stock instead of cash. This decision reflects the company's ongoing capital management strategy.

• · Interest payment date: June 30, 2026
• · Record date: June 1, 2026 at 5:00 p.m. New York City time
• · Interest will be paid in Series D Cumulative Convertible Preferred Stock rather than cash

20-05-2026

Diamondback Energy announced the transition of Travis D. Stice from Executive Chairman to non-executive Chairman effective May 20, 2026, as part of a previously disclosed leadership plan. At the 2026 Annual Meeting, stockholders elected 13 directors, approved executive compensation on an advisory basis, and ratified Grant Thornton as auditor. The board also determined to hold future advisory votes on executive compensation annually.

• · Travis Stice received 245,001,012 votes for and 4,645,408 against his election as director.
• · Proposal 2 (advisory vote on executive compensation) received 245,941,011 votes for and 3,547,122 against.
• · Proposal 3 (frequency of advisory vote) resulted in 246,338,007 votes for 1 year, 371,078 for 2 years, and 2,888,098 for 3 years.
• · Proposal 4 (ratification of Grant Thornton) received 263,223,128 votes for and 1,308,991 against.
• · The next advisory vote on frequency of future advisory votes will be no later than the 2032 annual meeting.

20-05-2026

Interlink Electronics held its 2026 annual meeting on May 19, 2026, with 89.28% of shares represented. All four director nominees were elected, and stockholders approved executive compensation, ratified LMHS, P.C. as auditor, and adopted the 2026 Omnibus Incentive Plan. All proposals passed with strong support, though the omnibus plan had the highest opposition (95,685 against).

• · Director election results: Steven Bronson received 12,706,374 for, 8,504 withhold; Joy Hou 12,705,258 for, 9,620 withhold; David Wolenski 12,706,421 for, 8,457 withhold; Maria Fregosi 12,708,121 for, 6,757 withhold.
• · Executive compensation advisory vote: 12,683,617 for, 26,308 against, 4,953 abstain.
• · Ratification of LMHS, P.C.: 14,045,812 for, 7,332 against, 9,086 abstain (no broker non-votes).
• · 2026 Omnibus Incentive Plan: 12,616,110 for, 95,685 against, 3,083 abstain.

20-05-2026

Pixelworks, Inc. held its 2026 Annual Meeting of Shareholders on May 20, 2026, where shareholders approved an amendment to the 2006 Stock Incentive Plan, increasing authorized shares by 300,000 to 2,940,278, and ratified Grant Thornton LLP as the independent auditor for fiscal 2026. All five director nominees were elected, and executive compensation was approved on an advisory basis. The filing reflects routine governance matters with no financial results or operational updates.

• · The 2026 Annual Meeting was held by telephone.
• · Broker non-votes totaled 1,970,855 for director elections and the stock plan and executive compensation proposals.
• · The stock incentive plan amendment was approved with 2,088,917 votes for, 226,671 against, and 17,380 abstentions.
• · Executive compensation advisory vote received 2,089,858 for, 233,448 against, and 9,662 abstentions.
• · Grant Thornton LLP ratification received 4,243,044 for, 57,853 against, and 2,926 abstentions (no broker non-votes on this proposal).
• · The Restated Plan was adopted by the Board on April 14, 2026, and the proxy statement was filed on April 17, 2026.

20-05-2026

OPAL Fuels Inc. subsidiary OPAL Fuels LLC amended its Series A-1 Preferred Units certificate on May 18, 2026, increasing the annual dividend rate from 8% to 12% and restructuring payment-in-kind options to cap in-kind payments at 2% per annum with the remaining 10% payable in cash. The amendment also revised change-of-control definitions, replaced event-of-default provisions with a trigger event framework that adds a penalty rate of up to 4% per annum, and removed delayed redemption conversion rights. While the higher dividend rate and cash payment requirement may pressure near-term cash flows, the enhanced protective provisions and penalty mechanisms could provide stronger investor protections.

• · The A&R COD does not provide Series A-1 holders with board appointment rights, unlike Series A holders.
• · Mandatory redemption can be requested upon a Change of Control, an uncured Trigger Event (60-day cure period), or on or after the 5th anniversary of March 6, 2026.
• · Delayed redemption conversion rights were removed; unredeemed units remain outstanding with all rights and preferences, including Trigger Event and penalty rate provisions.
• · Holders have no preemption or conversion rights under the A&R COD.
• · New 'Triggered Protective Provisions' become effective 30 days after a failed mandatory redemption, imposing restrictions on equity issuance, indebtedness, liens, tax distributions, asset dispositions, and discretionary capex.
• · Refinancing of the Intermediate Loan requires Requisite Holders consent for certain actions relating to Paragon JV if the applicable credit rating is below B+ (or equivalent).

20-05-2026

BlackRock Monticello Debt Real Estate Investment Trust filed an amendment (Form 10-Q/A) to its Q1 2026 quarterly report solely to include previously omitted Iran Threat Reduction and Syria Human Rights Act disclosure (Exhibit 99.1) and related certifications. The amendment does not change any financial results or reflect events after the original filing date. As of May 5, 2026, the company had 347,110 Class E, 5,600,925 Class F-I, and 2,745,561 Class F-S common shares outstanding, with no shares of other classes outstanding.

• · The amendment was filed on May 20, 2026, to add Exhibit 99.1 (Section 13(r) disclosure) and updated certifications under Rule 13a-14(a)/15d-14(a).
• · No financial statements are included in this amendment; it does not amend any disclosure under Items 307 or 308 of Regulation S-K.
• · The company is a non-accelerated filer, smaller reporting company, and emerging growth company.

20-05-2026

Freeport-McMoRan Inc. (FCX) and its subsidiary PT Freeport Indonesia entered into a new revolving credit agreement dated May 14, 2026, with a syndicate of lenders led by JPMorgan Chase Bank as administrative agent. The agreement establishes a revolving credit facility, includes financial covenants such as a total leverage ratio, and provides for joint and several liability between FCX and PT Freeport Indonesia. The specific commitment amounts and schedules were omitted from the filing as non-material, but the facility includes incremental commitment and maturity extension provisions.

• · The credit agreement includes a Total Leverage Ratio covenant (Section 6.06) with compliance certifications required quarterly.
• · The agreement provides for incremental revolving commitments (Section 2.20) and extension of maturity date (Section 2.21).
• · PT Freeport Indonesia is designated as a co-borrower with joint and several liability.
• · Financial reporting requirements include audited annual statements within 90 days and quarterly unaudited statements within 45 days.
• · The agreement contains customary representations, warranties, and events of default, including a Material Adverse Effect clause.

20-05-2026

Keurig Dr Pepper Inc. announced a regular quarterly dividend of $0.23 per share, payable on July 10, 2026, to shareholders of record as of June 26, 2026. The dividend was declared by the Board of Directors and disclosed via an 8-K filing on May 20, 2026.

• · The dividend is payable in U.S. dollars.
• · Record date for the dividend is June 26, 2026.
• · Payment date is July 10, 2026.
• · The filing was made under Items 8.01 and 9.01 of Form 8-K.

20-05-2026

CHOICE HOTELS INTERNATIONAL INC announced a leadership transition on May 20, 2026, with CEO Patrick S. Pacious stepping down effective immediately and Dominic E. Dragisich appointed as Interim CEO. Pacious will serve as an advisor through August 31, 2026, and remains a director nominee. The Board has initiated a search for a permanent CEO. The transition includes a separation agreement with Pacious providing cash severance of 200% of base salary and target bonus, continued equity vesting, and benefits through 2037. Dragisich receives a $500,000 cash bonus and $500,000 RSU award. The filing does not contain financial results or period-over-period comparisons.

• · Pacious's separation agreement includes cash severance equal to 200% of base salary and target bonus, plus pro rata bonus for 2026.
• · Pacious will continue vesting in equity awards for two years post-separation, except 2022 RSUs which vest pro rata.
• · Health insurance premium payments for Pacious from Separation Date until September 30, 2032.
• · Pacious remains a nominee for election at the Annual Meeting.
• · Dragisich previously served as CFO from March 2017 to September 2023.

20-05-2026

Teleflex Incorporated held its 2026 annual meeting on May 15, 2026, where stockholders elected seven directors, approved advisory compensation for named executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for 2026. All proposals passed with strong support, though the advisory vote on executive compensation received notable opposition with 1,632,219 votes against.

• · All seven director nominees received over 39.5 million votes in favor, with Michael J. Tokich receiving the highest support at 40,355,298 votes for and only 239,994 against.
• · The advisory vote on executive compensation passed with 38,990,583 for, 1,632,219 against, and 37,932 abstentions, representing about 4% opposition.
• · Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 passed with 40,460,649 for, 1,363,926 against, and 54,534 abstentions, with no broker non-votes.
• · Broker non-votes totaled 1,218,375 for each director election and the advisory compensation vote, indicating significant shares not voted by brokers on those items.

20-05-2026

On May 18, 2026, J. Carney Hawks was removed from the Board of Directors of Ferrellgas, Inc., the general partner of Ferrellgas Partners, L.P. and Ferrellgas, L.P. The removal was not related to any disagreement with the Company on operations, policies, or practices. It follows the conversion of all outstanding Class B Units into Class A Units on March 16, 2026, which eliminated the right of Class B holders to designate an independent director.

• · Mr. Hawks was originally appointed to the Board in 2021.
• · The conversion of Class B Units to Class A Units occurred on March 16, 2026.
• · The removal was effective May 18, 2026.

20-05-2026

Verra Mobility Corporation held its 2026 annual meeting on May 19, 2026, where three Class II directors were elected and executive compensation was approved on a non-binding advisory basis. Stockholders also ratified Deloitte & Touche as independent auditor for fiscal year 2026. Notably, director John H. Rexford received a substantial 33.3% withheld vote (46.7 million votes withheld), indicating significant shareholder dissent for that nominee.

• · Record date for the Annual Meeting was March 24, 2026, with 151,906,484 shares of Class A Common Stock outstanding and entitled to vote.
• · Broker non-votes totaled 4,653,513 for each director election and for proposals 2 and 3.
• · Executive compensation (Say-on-Pay) received 137,211,722 votes for, 2,759,518 against, and 393,789 abstentions.
• · Annual say-on-pay frequency was approved with 136,797,763 votes for 1 Year, 204,369 for 2 Years, 3,182,006 for 3 Years, and 180,891 abstentions.
• · Ratification of Deloitte & Touche received 144,877,651 votes for, 88,040 against, and 52,851 abstentions.
• · Patrick J. Byrne received 125,238,836 votes for and 15,126,193 withheld.
• · David M. Roberts received 136,040,667 votes for and 4,324,362 withheld.
• · John H. Rexford received 93,660,431 votes for and 46,704,598 withheld — a notable dissent level of 33.3%.

20-05-2026

Rigel Pharmaceuticals held its 2026 Annual Meeting on May 14, 2026, where stockholders approved amendments to the 2018 Equity Incentive Plan (adding 500,000 shares) and the 2000 Employee Stock Purchase Plan (adding 360,000 shares). Directors Alison Hannah, Walter Moos, and Raul Rodriguez were elected, and stockholders ratified Ernst & Young as independent auditor for fiscal 2026. The say-on-pay advisory vote was also approved.

• · The Amended 2018 Plan and Amended ESPP became effective immediately upon stockholder approval.
• · Broker non-votes were 3,406,029 for all director elections and most proposals, except ratification of Ernst & Young which had no broker non-votes.
• · The say-on-pay proposal received 9,013,480 for, 1,291,609 against, and 416,316 abstentions.

20-05-2026

Monroe Capital Enhanced Corporate Lending Fund declared a $0.20 per share dividend for Class I shares, payable June 24, 2026. As of April 30, 2026, the Fund reported a net asset value of $25.76 per Class I share, total net assets of $104.2 million, and a debt-to-equity ratio of 1.15x. The portfolio consisted of 39 companies with an aggregate fair value of $215.7 million, entirely in floating-rate debt investments, but the Fund had only $2.7 million in total public offering proceeds raised, with no Class S or Class D shares outstanding.

• · The Fund had no Class S or Class D shares outstanding as of April 30, 2026.
• · Weighted-average closing date annual EBITDA of portfolio companies was approximately $22.5 million.
• · The Fund's portfolio is concentrated in Services: Business (24.7%), High Tech Industries (16.7%), and Healthcare & Pharmaceuticals (16.3%).
• · The public offering has raised only $2.7 million out of a $1.0 billion maximum offering, indicating very limited public investor demand.
• · The Fund has sold approximately 3.95 million unregistered Class I shares to affiliates of the Adviser for $100.0 million, far exceeding public offering proceeds.

20-05-2026

Socket Mobile received a Nasdaq deficiency notice on May 19, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until November 16, 2026, to regain compliance. While the stock continues to trade on Nasdaq under SCKT, failure to cure could lead to delisting, adversely affecting liquidity and capital raising.

• · The deficiency letter has no immediate effect on listing; shares continue trading on Nasdaq Capital Market under SCKT.
• · If compliance not regained by Nov 16, 2026, Nasdaq may grant an additional 180-day period if the company meets other requirements and provides written notice.
• · Delisting could discourage broker-dealers from making a market, deter institutional investors, and materially reduce the stock's market price.

20-05-2026

Raymond James Financial, Inc. furnished an 8-K on May 20, 2026, disclosing its operating data for April 2026 via a press release attached as Exhibit 99.1. The filing is provided under Regulation FD and is not deemed filed for SEC liability purposes. No specific financial figures or period-over-period comparisons are included in the 8-K itself, limiting the ability to assess performance trends.

• · The press release was issued on May 20, 2026, and is attached as Exhibit 99.1.
• · The filing is furnished under Item 7.01 (Regulation FD Disclosure) and is not deemed filed for purposes of Section 18 of the Exchange Act.
• · The registrant is incorporated in Florida with its principal executive offices in St. Petersburg, Florida.

20-05-2026

Vivakor, Inc. reported a net loss of $4.58M for Q1 2026, improving from a $7.53M loss in Q1 2025. Total revenues decreased 47.9% YoY to $19.46M, while gross profit increased 20.3% to $5.72M. Cash and restricted cash fell sharply to $75k from $2.10M at year-end 2025, and the company had an accumulated deficit of $211.05M.

• · Accounts receivable net decreased to $2.20M from $3.53M, while related party receivables increased to $5.95M from $1.44M.
• · Allowance for credit losses on accounts receivable was $1.51M at March 31, 2026, compared to $0 at December 31, 2025.
• · Property and equipment net decreased to $57.14M from $58.30M, with $12.37M in construction in process.
• · Intangible assets net decreased to $7.32M from $7.52M.
• · Total current liabilities increased to $62.96M from $61.52M.
• · Net cash used in operating activities was $3.32M in Q1 2026, compared to essentially zero in Q1 2025.
• · No cash was paid for interest in Q1 2026, versus $218k in Q1 2025.
• · Basic and diluted net loss per share improved to $(2.32) from $(42.32) due to increased share count.
• · Weighted average common shares outstanding increased to 2,919,188 from 215,384.
• · Series A Preferred Stockholder Dividends of $2.20M were declared in Q1 2026, up from $1.59M in Q1 2025.

20-05-2026

Palvella Therapeutics, Inc. announced on May 20, 2026, that new positive clinical data from its Phase 3 SELVA and Phase 2 TOIVA studies were presented at the International Society for the Study of Vascular Anomalies World Congress 2026. The filing does not provide specific financial figures or period-over-period comparisons, only a qualitative update on clinical progress.

• · The press release was issued on May 20, 2026.
• · Data was presented at the International Society for the Study of Vascular Anomalies World Congress 2026.
• · The filing is an 8-K under Items 8.01 and 9.01, indicating an other event disclosure.

20-05-2026

Travel + Leisure Co. issued $900M of 6.250% senior secured notes due 2031, using proceeds to redeem its 6.625% secured notes due July 2026 and repay borrowings under its revolving credit facility. The notes are senior secured, not guaranteed, and include make-whole redemption provisions and a change of control put at 101%.

• · The notes are senior secured and rank equally with existing senior indebtedness, but are structurally subordinated to subsidiary obligations.
• · Optional redemption before June 1, 2028 requires a make-whole premium; after that date, redemption prices decline to par by June 1, 2030.
• · The indenture includes covenants restricting liens and sale-leaseback transactions, and cross-default triggers at $100M or 1.5% of consolidated total assets.
• · Certain initial purchasers may hold the 2026 Notes and receive proceeds from the redemption.

20-05-2026

Cosmos Health Inc. reported Q1 2026 revenue of $17.9M, up 30.7% YoY from $13.7M, driven by strong top-line growth. However, gross profit declined 32.6% to $1.4M (from $2.0M) due to a sharp increase in cost of goods sold, and the net loss widened to $2.8M from $0.8M. Operating cash flow remained negative at -$1.1M, and total assets fell 4.7% to $62.4M, while stockholders' equity improved to $19.8M.

• · Total current assets decreased to $36.9M from $38.4M (Dec 31, 2025).
• · Total current liabilities decreased to $34.1M from $38.3M (Dec 31, 2025).
• · Convertible notes payable (current) dropped sharply to $0.6M from $2.1M.
• · Derivative liability decreased to $1.1M from $1.3M.
• · Lines of credit decreased to $7.9M from $9.2M.
• · Operating expenses increased 23.7% YoY to $3.6M.
• · Interest expense more than doubled to $0.4M from $0.2M.
• · Loss on digital assets of $0.4M in Q1 2026 vs. $0 in Q1 2025.
• · Foreign currency translation loss of $0.3M in Q1 2026 vs. gain of $1.0M in Q1 2025.
• · Total comprehensive loss of $3.1M in Q1 2026 vs. comprehensive income of $0.2M in Q1 2025.
• · Net cash used in operating activities worsened to -$1.1M from -$0.2M.
• · Net cash used in investing activities was -$0.7M, primarily for purchase of digital assets ($1.1M).
• · Net cash provided by financing activities was $0.3M, down from $0.6M.
• · Proceeds from sale of common stock were $1.8M in Q1 2026 vs. $0 in Q1 2025.
• · Debt exchanges of $1.0M occurred in Q1 2026.
• · Conversion of convertible debt into common stock of $1.2M in Q1 2026.

20-05-2026

Envirotech Vehicles (EVTV) announced a definitive merger agreement with Azio AI at a $750M valuation, up from a prior $480M LOI, supported by a fairness opinion. The combined entity will focus on AI infrastructure, data centers, and bitcoin mining. However, the transaction is subject to SEC review and shareholder approval, and forward-looking statements highlight significant risks and uncertainties.

• · The merger agreement was approved by the boards of both companies.
• · Post-merger leadership includes Chris Young as CEO and Chairman, Elgin Tracy overseeing infrastructure deployment, and Jason Maddox supporting executive operations.
• · Near-term priorities include filing Form S-4, deploying 11 MW of secured power, and pursuing up to 100 MW of additional capacity at the existing site.
• · Revenue model includes GPU/server rack sales, co-development of data centers, bitcoin mining, and hosting/leasing arrangements.
• · The transaction is subject to SEC review and shareholder approval.

20-05-2026

Angel Oak Mortgage REIT, Inc. entered into a stock repurchase agreement to buy back $15 million of its common stock from Xylem Finance LLC at a 3% discount to the 10-day VWAP. Concurrently, the Shareholder Rights Agreement will be terminated and board member Vikram Shankar will resign. The transaction is expected to close on May 20, 2026.

• · The repurchase price is based on the 10-day VWAP less a 3% discount.
• · The Shareholder Rights Agreement, dated June 21, 2021, will be terminated upon Mr. Shankar's resignation.
• · The Selling Stockholder permanently waives its Applicable Registration Rights under the Registration Rights Agreement.
• · The Selling Stockholder owns 3,652,673 shares of common stock.
• · The repurchase is for $15,000,000 worth of shares, with the exact number determined by dividing $15,000,000 by the Share Price.

20-05-2026

On May 14, 2026, Modular Medical, Inc. awarded stock options to two named executive officers: 11,218 options to Chairman/President/CFO/Treasurer Paul DiPerna and 4,674 options to COO Kevin Schmid, with an exercise price of $3.46 per share. The options vest over three years (one-third on May 14, 2027, and monthly thereafter) and expire on May 14, 2036. No financial results or period-over-period comparisons are included in this filing.

• · The stock options were granted under the Amended and Restated 2017 Equity Incentive Plan.
• · Vesting schedule: one-third on May 14, 2027, and 1/24th monthly thereafter.
• · Options expire on May 14, 2036.

20-05-2026

Motorola Solutions, Inc. held its 2026 Annual Meeting on May 18, 2026, where shareholders elected all director nominees, ratified PricewaterhouseCoopers LLP as the independent auditor for 2026, and approved executive compensation on an advisory basis. While all director nominees received majority support, Gregory Q. Brown (5.7M against), Kenneth D. Denman (9.2M against), and Joseph M. Tucci (5.4M against) faced notable opposition, and the advisory vote on executive compensation had 11.3M against votes, indicating some shareholder dissent.

• · All director nominees were elected to serve a one-year term until their successors are elected and qualified or until earlier death or resignation.
• · The ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 passed with 148,106,794 votes for, 512,498 against, and 338,605 abstentions, with no broker non-votes.
• · The advisory vote on executive compensation received 121,400,188 votes for, 11,342,954 against, and 414,605 abstentions, with 15,800,150 broker non-votes.
• · Broker non-votes totaled 15,800,150 for each director election and the executive compensation proposal, but were not applicable for the auditor ratification.

20-05-2026

Cleveland-Cliffs Inc. held its Annual Meeting on May 14, 2026, where all eight director nominees were elected, and shareholders approved advisory say-on-pay and ratified Deloitte & Touche as auditor for 2026. All proposals passed with strong support, though say-on-pay received about 15% against votes.

• · Record date for the meeting was March 16, 2026.
• · Broker non-votes totaled 101,429,760 shares for director elections and say-on-pay.
• · Ratification of Deloitte & Touche received 427,885,151 votes for, 9,601,163 against, and 1,389,633 abstentions.

20-05-2026

Benchmark 2026-B43 Mortgage Trust filed an 8-K/A on May 20, 2026, amending its April 30, 2026 Form 8-K to replace and supersede several exhibits with updated versions. The amendments include corrective revisions to the Underwriting Agreement, conformed signatures and a Mortgage Loan Schedule in the Pooling and Servicing Agreement, a dated Phoenix Industrial Portfolio XV Co-Lender Agreement, and conformed signatures and schedules in seven Mortgage Loan Purchase Agreements. No financial data or performance metrics were provided in this filing.

• · The amendment replaces the Underwriting Agreement (Exhibit 1) with a version containing corrective revisions.
• · The Pooling and Servicing Agreement (Exhibit 4.1) now includes conformed signatures, a Mortgage Loan Schedule (Exhibit B), an address for notices to Goldman Sachs Bank USA, a corrected address for Trimont LLC, common codes for certain certificate classes, and other clerical revisions.
• · The Phoenix Industrial Portfolio XV Co-Lender Agreement (Exhibit 4.5) is now dated and includes conformed signatures.
• · Seven Mortgage Loan Purchase Agreements (Exhibits 99.1–99.7) from Citi Real Estate Funding Inc., German American Capital Corporation, Goldman Sachs Mortgage Company, Bank of America, Barclays Capital Real Estate Inc., UBS AG New York Branch, and Bank of Montreal now include conformed signatures and a Mortgage Loan Schedule (Exhibit A).
• · The filing is dated May 20, 2026, and was signed by Richard Simpson as President of Citigroup Commercial Mortgage Securities Inc.

20-05-2026

Foxx Development Holdings Inc. reported a net loss of $36.3M for the three months ended March 31, 2026, compared to a net loss of $4.1M in the same period last year, driven by a $25.9M impairment of right-of-use assets and a gross loss of $1.5M versus a gross profit of $0.7M. For the nine-month period, net loss widened to $43.4M from $4.9M, while revenue declined 12.3% to $45.6M. However, cash from operations turned positive at $1.3M, and cash balance increased to $3.2M from $1.9M at June 30, 2025.

• · Gross loss of $1.5M for Q3 FY26 vs gross profit of $0.7M in prior year quarter.
• · Operating expenses surged to $32.5M from $4.2M, primarily due to $25.9M impairment of right-of-use assets.
• · Interest expense increased to $2.3M from $1.6M for the quarter.
• · Accounts payable – supplier financing rose to $32.3M from $26.2M.
• · Total liabilities more than doubled to $75.9M from $31.4M.
• · Allowance for credit losses on accounts receivable increased to $1.8M from $0.6M.
• · Inventories decreased to $7.0M from $12.7M.
• · Contract assets dropped to $41.7K from $454.8K.
• · Cash provided by operating activities was $1.3M for the nine months, compared to cash used of $4.7M in the prior period.
• · Non-cash impairment of right-of-use assets of $25.9M and inventory impairment of $4.7M were recorded.

20-05-2026

Wells Fargo & Company issued $6.0 billion in Medium-Term Notes, Series Y, on May 20, 2026, comprising $2.25 billion Senior Redeemable Fixed-to-Floating Rate Notes due 2029, $500 million Senior Redeemable Floating Rate Notes due 2029, and $3.25 billion Senior Redeemable Fixed-to-Floating Rate Notes due 2032. The filing includes related exhibits and legal opinions. No financial performance data or period comparisons are provided.

• · The Notes are issued under Registration Statement on Form S-3 (File No. 333-287868).
• · The filing includes exhibits: forms of notes, legal opinion from Faegre Drinker Biddle & Reath LLP, and consent.

20-05-2026

Stellar Bancorp, Inc. (STEL) disclosed supplemental disclosures to its proxy statement/prospectus regarding its proposed merger with Prosperity Bancshares, Inc., following three shareholder lawsuits and demand letters alleging disclosure deficiencies. The supplemental disclosures provide additional details on pre-merger discussions with other potential acquirers (Company B, Company C, Company D) and expand on the financial advisor's valuation analyses. Stellar and Prosperity deny any wrongdoing but are making the disclosures to avoid litigation delays, with the special shareholder meeting scheduled for May 27, 2026.

• · Three lawsuits filed in New York Supreme Court: Jackson v. Stellar Bancorp (May 5, 2026), Kent v. Stellar Bancorp (May 5, 2026), and Zalvin v. Stellar Bancorp (May 13, 2026).
• · Stellar also received demand letters from purported shareholders.
• · Stellar and Prosperity deny all allegations and assert no additional disclosure is required, but are making supplemental disclosures to avoid litigation risk.
• · Supplemental disclosures reveal Stellar had NDA discussions with Company B (Sept 2025), Company C (Oct 2025), and Company D (Nov 2025) before signing with Prosperity.
• · Stellar's financial advisor (KBW) selected companies analysis: price-to-tangible book value multiples ranged 0.93x–2.53x; price-to-2026E EPS 9.9x–13.3x; price-to-2027E EPS 7.9x–12.3x.
• · Prosperity selected companies analysis: price-to-tangible book value multiples 1.02x–2.40x; price-to-2026E EPS 7.7x–13.8x; price-to-2027E EPS 7.1x–13.3x.
• · Selected transactions analysis: price-to-tangible book value multiples 0.99x–2.34x; pay-to-trade ratios 0.55x–1.19x; price-to-LTM EPS 12.4x–27.6x; core deposit premiums 0.0%–10.6%.
• · Special meeting of Stellar shareholders scheduled for May 27, 2026.
• · The merger is expected to be accretive to Prosperity's 2026 EPS by 2.7% and 2027 EPS by 9.2%, but dilutive to tangible book value per share by 7.8% at closing.